Journal Mobile Options
Table of Contents
Vol. 53, No. 4, 1996
Issue release date: 1996
Oncology 1996;53:275–280

Bone-Specific Alkaline Phosphatase in Plasma as Tumour Marker for Osteosarcoma

Liu P.P.L. · Leung K.S. · Kumta S.M. · Lee K.M. · Fung K.P.
aDepartment of Orthopaedics and Traumatology, bLee Hysan Clinical Research Laboratories and cDepartment of Biochemistry, Faculty of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The levels of bone-specific alkaline phosphatase (BALP) in plasma and tumour tissue samples of 20 Chinese patients with osteosarcoma in Hong Kong were measured by the wheat germ lectin precipitation technique. The plasma BALP levels in these patients were significantly higher than those of the normal subjects (p < 0.001), and also significantly higher than those of patients with benign bone tumor and those of patients with malignant tumor metastasized to the bone (p < 0.0001). Considering the prognostic value of BALP for osteosarcoma, the plasma BALP levels at the time of diagnosis were found to be significantly related to the rate of disease recurrence (p < 0.05). Furthermore, at the time of relapse, the plasma BALP levels in the group of recurrent osteosarcoma patients were significantly higher than those of osteosarcoma patients showing no recurrence (p < 0.05). When ALP was assayed in the tumor tissue, the BALP levels were also significantly higher than those of the control cortical bone extracts in the same group of patients (p < 0.05). We conclude that plasma BALP is a sensitive and specific biochemical parameter in the diagnosis and the subsequent monitoring of osteosarcoma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50